Gain of function, loss of control - A molecular basis for chronic myeloproliferative disorders

Haematologica

Volumn 90, Issue 7, 2005, Pages 871-874

  Cazzola, Mario ^a   Skoda, Radek ^b  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2; PROTEIN TYROSINE KINASE;

CANCER GENETICS; CELL GROWTH; CELL SURVIVAL; CHROMOSOME ABERRATION; CHRONIC DISEASE; CHRONIC MYELOID LEUKEMIA; EDITORIAL; GENE MUTATION; HUMAN; MOLECULAR GENETICS; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; POLYCYTHEMIA VERA; THROMBOCYTHEMIA;

CHROMOSOME ABERRATIONS; GENE EXPRESSION REGULATION; HUMANS; JANUS KINASE 2; LEUKEMIA; LOSS OF HETEROZYGOSITY; MODELS, BIOLOGICAL; MODELS, GENETIC; MUTATION; MYELOPROLIFERATIVE DISORDERS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS;

EID: 22544481483     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (36)

1. Dameshek W. Some speculations on the myeloproliferative syndromes. Blood 1951;6:372-5.
2. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003;348:1201-14.
3. Chalandon YSchwaller J. Targeting mutated tyrosine kinases and their signalling pathways in haematological malignancies. Haematologica 2005;90:XXX.
4. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-8.
5. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-61.
6. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-97.
7. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-90.
8. Steensma DP, Dewald GW, Lasho TL, Powell HL, McClure RF, Levine RL, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and the myelodysplastic syndrome. Blood 2005:Apr 28; [Epub ahead of print].
9. Zhao R, Xing S, Li Z, Fu X, Li Q, Krantz SB, et al. Identification of an acquired JAK2 mutation in Polycythemia vera. J Biol Chem 2005:Apr 29; [Epub ahead of print].
10. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005:May 26; [Epub ahead or print].
11. Adamson JW, Fialkow PJ, Murphy S, Prchal JFSteinmann L. Polycythemia vera: stem-cell and probable clonal origin of the disease. N Engl J Med 1976;295:913-6.
12. Liu E, Jelinek J, Pastore YD, Guan Y, Prchal JFPrchal JT. Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin. Blood 2003;101:3294-301.
13. el-Kassar N, Hetet G, Briere JGrandchamp B. Clonality analysis of hematopoiesis in essential thrombocythemia: advantages of studying T lymphocytes and platelets. Blood 1997;89:128-34.
14. Harrison CN, Gale RE, Machin SJLinch DC. A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications. Blood 1999;93:417-24.
15. Shih LY, Lin TL, Lai CL, Dunn P, Wu JH, Wang PN, et al. Predictive values of X-chromosome inactivation patterns and clinicohematologic parameters for vascular complications in female patients with essential thrombocythemia. Blood 2002;100:1596-601.
16. Prchal JFAxelrad AA. Letter: Bone-marrow responses in polycythemia vera. N Engl J Med 1974;290:1382.
17. Lacombe C, Casadevall NVaret B. Polycythaemia vera: in vitro studies of circulating erythroid progenitors. Br J Haematol 1980;44:189-99.
18. Zwicky C, Theiler L, Zbaren K, Ischi ETobler A. The predictive value of clonogenic stem cell assays for the diagnosis of polycythaemia vera. Br J Haematol 2002;117:598-604.
19. Kralovics R, Buser AS, Teo SS, Coers J, Tichelli A, van der Maas AP, et al. Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders. Blood 2003;102:1869-71.
20. Cazzola M. Serum erythropoietin concentration as a diagnostic tool for polycythemia vera. Haematologica 2004;89:1159-60.
21. Mossuz P, Girodon F, Donnard M, Latger-Cannard V, Dobo I, Boiret N, et al. Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis. Haematologica 2004;89:1194-8.
22. Dai CH, Krantz SB, Means RT, Jr., Horn ST, Gilbert HS. Polycythemia vera blood burst-forming units-erythroid are hypersensitive to interleukin-3. J Clin Invest 1991;87:391-6.
23. Dai CH, Krantz SB, Dessypris EN, Means RT, Jr., Horn ST, Gilbert HS. Polycythemia vera. II. Hypersensitivity of bone marrow erythroid, granulocyte-macrophage, and megakaryocyte progenitor cells to interleukin-3 and granulocyte-macrophage colony-stimulating factor. Blood 1992;80:891-9.
24. Correa PN, Eskinazi DAxelrad AA. Circulating erythroid progenitors in polycythemia vera are hypersensitive to insulin-like growth factor-1 in vitro: studies in an improved serum-free medium. Blood 1994;83:99-112.
25. Axelrad AA, Eskinazi D, Correa PNAmato D. Hypersensitivity of circulating progenitor cells to megakaryocyte growth and development factor (PEG-rHu MGDF) in essential thrombocythemia. Blood 2000;96:3310-21.
26. Cazzola MSkoda RC. Translational pathophysiology: a novel molecular mechanism of human disease. Blood 2000;95:3280-8.
27. Cazzola M, Bergamaschi G, Tonon L, Arbustini E, Grasso M, Vercesi E, et al. Hereditary hyperferritinemia-cataract syndrome: relationship between phenotypes and specific mutations in the iron-responsive element of ferritin lignt-chain mRNA. Blood 1997;90:814-21.
28. Wiestner A, Schlemper RJ, van der Maas APSkoda RC. An activating splice donor mutation in the thrombopoietin gene causes hereditary thrombocythaemia. Nat Genet 1998;18:49-52.
29. Kralovics R, Guan YPrchal JT. Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Exp Hematol 2002;30:229-36.
30. Parganas E, Wang D, Stravopodis D, Topham DJ, Marine JC, Teglund S, et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell 1998;93:385-95.
31. Helleday T. Pathways for mitotic homologous recombination in mammalian cells. Mutat Res 2003;532:103-15.
32. Raghavan M, Lillington DM, Skoulakis S, Debernardi S, Chaplin T, Foot NJ, et al. Genome-wide single nucleotide polymorphism analysis reveals frequent partial uniparental disomy due to somatic recombination in acute myeloid leukemias. Cancer Res 2005;65:375-8.
33. Shannon KVan Etten RA. JAKing up hematopoietic proliferation. Cancer Cell 2005;7:291-3.
34. Kaushansky K. On the molecular origins of the chronic myeloproliferative disorders: it all makes sense. Blood 2005;105:4187-90.
35. Lacronique V, Boureux A, Valle VD, Poirel H, Quang CT, Mauchauffe M, et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 1997;278:1309-12.
36. Zhao S, Zoller K, Masuko M, Rojnuckarin P, Yang XO, Parganas E, et al. JAK2, complemented by a second signal from c-kit or flt-3, triggers extensive self-renewal of primary multipotential hemopoietic cells. Embo J 2002;21:2159-67.